Abstract 558P
Background
In Asian populations, there is a lack of substantial real-world data for brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor for patients with NSCLC. The aim of this study was to analyze real-world brigatinib treatment outcomes and dosing patterns in patients with ALK+ NSCLC who had received prior crizotinib in South Korea.
Methods
This retrospective, non-interventional cohort study used Health Insurance and Review Assessment claims data. The study included patients (>20 years old) who initiated brigatinib from 19 April 2019 to 31 March 2021 and who received crizotinib before brigatinib. We assessed patients' characteristics, treatment discontinuation, dose reduction, overall survival (OS) and adherence. Time to treatment discontinuation (TTD), time to dose reduction and OS were analyzed using Kaplan-Meier estimates. Patients whose proportion of days covered (PDC) was ≥0.8 were defined as treatment adherent.
Results
A total of 174 crizotinib-refractory patients (56.9% male; 27.1% brain metastasis history) with ALK+ NSCLC were included in the analysis (median [range] follow-up: 18 [0–34] months); the median treatment duration of prior crizotinib was 17 months. For brigatinib as second-line treatment, the median TTD was 25 months (95% CI:15.2–NE). 1- and 2-year treatment continuation rates were 63.2% and 51.5%, respectively. Median OS was not reached during the study period. The 2-year OS rate was 68.7%. 88.5% of patients reached full-dose brigatinib (180 mg/day) during treatment duration. The probability of continuing brigatinib at full dose (180 mg/day) or at peak dose (<180 mg/day) was 79.7% and 75.6% at 1 and 2 years, respectively. Overall, 93.1% of patients were adherent to brigatinib during treatment. The median PDC of brigatinib treatment was 0.98.
Conclusions
This is the first nationwide, real-world study of brigatinib treatment in a large cohort of crizotinib-refractory ALK+ NSCLC patients in South Korea. In this study, brigatinib demonstrated a longer treatment duration than in published clinical trials, as well as a favorable 2-year OS rate and high adherence. Second-line brigatinib treatment is of benefit in a real-world setting in South Korea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Takeda.
Funding
Takeda.
Disclosure
J.H. Nam, S.H. Kwon: Financial Interests, Personal and Institutional, Research Grant: Takeda. B. Kim, S. Ha: Financial Interests, Personal, Full or part-time Employment: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract